is...(putting together master plan to take over the world)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Someone got out with a nice chunk 9,107 shares
Sooner or later all those shares will go into tighter hands I think
NNAB turning out ok 15s 16s all grabbed .20s up. Should of got a lot more
PRLX .185 very surprised it still trading this low I would of thought .30s or 40s by now and .70s .80s when merger is complete. This is going to be huge.imo
PRLX .185 very nice one. 50 million dollar merger here and super low pps This one has massive potential.imo
Cool nice one, DFCO getting active again? very low .0017
Got a point there. I got such high aspirations for this one. Normally I dont hold stocks long term but there are exceptions to my rules, EXPL is one of them.
Cant wait til it starts trading better and higher. Back to waiting and disappointing - Something has to come out in next two weeks I think
Is that OS correct? Man that is huge and crazy its trading so high. They must have something smoking to make it up there
CSKH .0009 asking very cheap imo
DGI F .0043 hall of fame merger stock said to once run again soon from what I am hearing .05 starting .20 min then stars imo
Once .004s cleared out .01s will fall imo
DGI F .0042 Merger time Hall of Fame doing it again imo
PRLX .185 Still waiting on that merger. Should be a solid play. someone got some cheapies this am. A 50 million dollar merger, this should be trading .75 after it happens.imo
Edit - - They also put out PR a little while ago. NNAB .155 looks like they did an offering at .10 and had a PR below in March. Bid went away though. I dont like seeing VFIN on ask and not willing to put a bid in at .10 or at least higher than .03...
Monday, May 05 2014 12:34 PM, EST NanoAntibiotics to Begin Trading on the OTC Markets Marketwire "Press Releases"
BOSTON, MA -- (Marketwired) -- 05/05/14 -- NanoAntibiotics Inc. (OTCQB: NNAB) (the "Company"), a development stage nano-biotechnology company focused on the discovery, development, and commercialization of new anti-infective drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens, is pleased to announce that it has been informed that trading of its stock is to begin on the OTC Markets.
"We are excited to be making our debut in the public marketplace and committed to providing our investors with access to information on the Company," says Rajah Menon, NanoAntibiotics President and Director. "We are constantly advancing towards our goal of creating the world's ultimate weapon against bacteria, the first drug that will solve the bacterial efflux issue. Progress is continuing in the development of our platform that will selectively target and block the efflux pump in variant antibiotic resistant bacteria."
Antibiotic resistance is becoming a worldwide problem as new forms of resistance can cross countries and continents with ease. Each year in the United States , more than 2 million people acquire serious infections with bacteria that are resistant to one or more of the antibiotics designed to treat those infections, according to the Centers for Disease Control and Prevention . At least 23,000 people die each year as a direct result of these antibiotic resistant infections and many more die from other conditions that were complicated by these infections.
"The development of multi-drug resistant efflux pumps are a major contributor to today's growing epidemic of antibiotic resistance in both Gram-negative and Gram-positive bacteria," comments Dr. Harold Landa , MD., FCCP, a scientific advisor to NanoAntibiotics. "Bacteria use multiple defenses to render antibiotics harmless, including efflux pumps, which transport drugs that actually penetrate the cell back outside of cell walls to protect their nucleus. Utilizing nano-technologies to inhibit efflux pump activity so antibiotics can quickly destroy bacteria has the potential to revitalize the efficacy of many current antibiotics as well as chart a course for new drug discoveries."
Separately, NanoAntibiotics' management would like to provide answers to questions that have been presented as the Company prepared to enter the public domain. The most frequently asked questions are addressed as follows:
Question: Would you please give us a background about NanoAntibiotics?
Answer: NanoAntibiotics was incorporated in April 2013 as a company focused on developing innovative new anti-infective drugs to combat multi-drug resistant bacteria. With our proprietary technology and scientific resources, it was an opportune time to launch the company in the antibiotics sector due to generous federal incentives, changing regulatory framework and growing need to develop alternative therapies to combat antibiotic resistance. It is well known that multi-drug resistant superbugs have become more prevalent and problematic and are becoming a healthcare and financial nightmare here in the USA . Against this backdrop, several large biotech companies are beginning to get back into antibiotics, leaving us in what we believe is an excellent position to advance our compounds and company.
Question: Can you please explain the reason for going public?
Answer: The main reason for going public is to use the capital markets to fund drug development, attract key talent to our company and, lastly, to acquire key technology. I see the success of Cellceutix Corporation, where my father is CEO, and believe that we can achieve rapid growth as well by being a smart and nimble public company. An example of this was their ability to acquire assets from a bankrupt Polymedix, Inc. using cash and stock in bankruptcy court, all accomplished in a short period of time.
Question: Please tell me if you have any affiliation with Cellceutix?
Answer: NanoAntibiotics and Cellceutix are two separate companies that both now happen to be working on antibiotics. NanoAntibiotics was incorporated before Cellceutix had anything to do with Polymedix and antibiotics. I read about the Polymedix bankruptcy and wished at the time that we had the resources to go out and acquire it. Ironically, I guess if NanoAntibiotics would have been established sooner then we ultimately would have been bidding against Cellceutix. I have to give credit to Cellceutix for jumping at the opportunity and successfully acquiring it. Actually, that fits in with our strategy of looking for and acquiring unique technologies that meet our business criteria to grow NanoAntibiotics.
Question: What is NanoAntibiotics' current technology?
Answer: NanoAntibiotics is developing novel nano anti-infective drugs to combat multi-drug resistant bacteria. We are developing a nano efflux pump inhibitor and novel nano antibiotics. I know the first thing that comes to most peoples' mind when using the word "pump" is an actual pump, or some type of extracorporeal medical device. The efflux pump in bacteria is nothing of the sort; it is a matrix of transport proteins involved with removing antibiotics from inside cells. In short, during the pathogenesis of infections, bacteria are able to grow and spread through intrinsic recognition of a drug as foreign and dangerous, triggering a response to "pump" the antibiotic outside its cell walls. The efflux pumps are a key defense mechanism of bacteria that prevents antibiotics from reaching their target and killing it, thus rendering many of today's antibiotics as ineffective. There is quite extensive literature published about this in peer-reviewed medical journals documenting the "learning ability" of bacterium to eliminate drugs from their core. Our Nano Efflux Pump Inhibitor is going after a leading cause of superbug resistance, the ability of bacteria to use their efflux defense.
We are working on making once bacteria-destroying antibiotics effective again. How we are working to do that is by packaging highly purified efflux pump compounds into a nano delivery system, targeting and delivering into the bacteria these large efflux pump inhibitors, effectively stopping the bacteria's drug extrusion ability. These highly purified efflux pump inhibitor compounds that we are researching are proven to not damage mammalian cells. Our goal is to develop a nano efflux pump inhibitor platform that can be easily modified for specific applications for the treatment of bacteria and deadly superbugs.
We have announced successful preliminary laboratory studies on one of our efflux pump inhibitor compounds against certain gram-positive bacteria. Additional studies are ongoing combining our compounds with approved antibiotics against multi-drug resistant bacteria. We look forward to releasing the results of this research in the near future.
Further, we have identified key nano antibiotic compounds from a leading researcher in the field of nanomedicine. We have recently begun studies testing these compounds as well.
Question: Where do you see NanoAntibiotics in the future?
Answer: We already see NanoAntibiotics growing quickly since inception, which we attribute to our innovative compounds and methodology to focus on nano-technology and efflux pump inhibition. We also see an interesting trend where large pharmaceutical companies are licensing compounds that don't necessarily fit their current business model to smaller biotechs, which dovetails with our acquisition and partnering plans. We believe that investors already see the potential as measured by our initial capital raise that was oversubscribed almost immediately. On that point, we feel that we are well positioned to advance our novel compounds from the lab to the clinic and grow into a formidable biotech going forward. There are no FDA approved drugs on the market for efflux pump inhibition, which presents a compelling opportunity. Consider that Mpex Pharmaceuticals partnered with GlaxoSmithKline to develop an efflux pump inhibitor, receiving $8.5 million upfront and a commitment from GSK for commercial milestone payments of up to $250 million for each product candidate in addition to tiered royalties. Our goal is to achieve a similar position in the future.
Bacteria Efflux Pumps:
Bacteria efflux pumps are intrinsic defense mechanisms that expel antibiotics before they reach their target and kill the bacteria. These pumps reside in bacterial cell walls and are a leading cause of multi-drug resistance. There are currently no anti-microbial drugs in use to inhibit the activity of these efflux pumps. There is a need for an effective pump inhibitor which would restore the potency of once effective antibiotics which have been rendered insensitive.
About NanoAntibiotics Inc.
NanoAntibiotics is a developmental stage nano-biotechnology company focused on the development and commercialization of novel therapeutics for multi-drug resistant gram-positive and gram-negative bacteria (also known as Superbugs).
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause NanoAntibiotics' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. NanoAntibiotics has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are NanoAntibiotics' need for, and the availability of, substantial capital in the future to fund its operations and research and development. The fact that NanoAntibiotics' compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in NanoAntibiotics' filings with the Securities and Exchange Commission . You should not place undue reliance on any forward-looking statements. NanoAntibiotics undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
INVESTOR AND MEDIA CONTACT: NanoAntibiotics Inc. Elliot Ehrlich (305) 515-4118 Email Contact
Source: NanoAntibiotics Inc.
NanoAntibiotics Provides Update on Its Novel Efflux Pump Inhibitor
SURFSIDE, FL, Mar 27, 2014 (Marketwired via COMTEX) -- NanoAntibiotics (OTCBB: NNAB) (the "Company"), a development stage nano-biotechnology company focused on the discovery, development, and commercialization of new anti-infective drugs to meet the growing clinical need created by multi-drug resistant bacterial pathogens, is pleased to report successful preliminary in vitro results on its novel efflux pump inhibitor.
The current study involved testing for efflux pump inhibition in Staphylococcus epidermis, a common gram-positive bacterium. In the study, the bacteria were incubated with a tracer dye to observe real time monitoring of its membrane transport systems. The results showed that the bacteria treated with our efflux pump inhibitor demonstrated retention of the tracer dye (showing they were not able to expel the dye), whereas no dye retention was observed in the untreated bacteria. Further studies are ongoing.
The company is excited about these results and its continuing progress to identify and optimize key nano efflux pump inhibitors to "target" and "block" some of the most deadly gram-positive and gram-negative bacteria.
Bacteria Efflux Pumps:
Bacteria efflux pumps are intrinsic defense mechanisms that expel antibiotics before they reach their target and kill the bacteria. These pumps reside in bacterial cell walls and are a leading cause of multi-drug resistance. There are currently no anti-microbial drugs in use to inhibit the activity of these efflux pumps. There is a need for an effective pump inhibitor which would restore the potency of once effective antibiotics which have been rendered insensitive.
About NanoAntibiotics, Inc.
NanoAntibiotics is a developmental stage nano-biotechnology company focused on the development and commercialization of novel therapeutics for multi-drug resistant gram-positive and gram-negative bacteria (also known as Superbugs).
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause NanoAntibiotics' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. NanoAntiobiotics has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are NanoAntibiotics' need for, and the availability of, substantial capital in the future to fund its operations and research and development. The fact that NanoAntibiotics' compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in NanoAntibiotics' filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. NanoAntibiotics undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Contact:
INVESTOR AND MEDIA CONTACT:
NanoAntibiotics, Inc.
Elliot Ehrlich
Email Contact
SOURCE: NanoAntibiotics
(C) 2014 Marketwire L.P. All rights reserved.
-0-
SUBJECT CODE: Pharmaceuticals and Biotech:Biotech
http://www.otcmarkets.com/stock/NNAB/news
In my experience its always a good sign when someone sells small lots at the bid. Only one reason to do that.
CEO isnt allowed to sell much into the market and he owns a huge chunk. Will see when filed. This has been a seesaw and not my forte but I Think it can go to .01 to .02 eventually with right PRs.
CDIF .0027 starting to heat up again. Had several free non paid promos, has acquisitions, updates to filings, just about all debt reduced, new directors coming etc. Should make for a good month or 2 or 3 coming.
Sometimes I like to think that.lol
I was thinking that if I bought 5k or 10k at .15 or .20s that they can be sold later at 1.00 or maybe much much higher with FS. I think low OS is much better than high OS. Liquidity is overrated. Its all about buying dollar amounts and selling dollar amounts for high % gains. There is no difference from buying 750k at .001 and getting 5k at .15 to me. If I can sell 750k at .005 on a runner and sell 5k at .75 its still the same gains you see? You would still end up with 3750 in your account. But the lower OS is less hassle and competition to me. Less riffraff's to deal with.
It would be so nice if CDIF could go .003 to .0035 again. That would boost my optimism on the stock very much.
Watched 3 of 4 Pirates of Caribbean over the weekend. Getting meself bucked up for the gold arhhH!
I didnt know he was in the shipwreck business. I own another co that is into that symbol EXPL which traded as high as 1.00+ recently.
EARH gave two updates recently so I think what the CEO is saying looks very promising. I may add some of this under .10. I think it probably has .20 potential. We will see what the future holds. Updating filings with SEC is most important to me. CEO says 90-120 days. Will give him benefit of doubt and trust him on timeline.
NNAB .155 asking. OTC Pink just started trading. Dont have any of this. Should be listed as OTCQB though from OTCM Webby
CATA not dying out. Went down a bit but now back up. Maybe there is something going on here.
Yeah really. I should of checked his other posts last time. He does that on every board. He should be banned from IHUB from that bs.
PPCH .09x.10 Hasnt had much activity before. Australian pharma co. Was .30-.40 before but now got 100k on ask @ .10. Not sure if its a goodie or not.
EARH .048 Guess they answered the SEC reporting question in the lasted shareholder update. Looks like a lot of positive activity with this stock. Sounds like a decent CEO who is doing the right things.
Mike Johnson CEO of Earth Dragon Resources, Inc. states, "It has been a challenging road over the last two years, but we find ourselves on a very exciting path. We are rapidly moving toward being fully-compliant with our SEC reporting requirements and look to further grow of our PlasmaGenix family of innovative products and services both domestic and international. I look forward to assisting PlasmaGenix team in becoming a global leader in the regenerative medicine field.”
Full PR:
Earth Dragon Resources, Inc. Announces Shareholder Update
Print
Alert
Earth Dragon Resources, Inc. Announces Shareholder Update Including Returning to Fully-Reporting Status and Board Approval to Reduce Authorized Shares by over 90 Percent
La Jolla, CA / ACCESSWIRE / April 14, 2014 / Earth Dragon Resources, Inc. (OTC – EARH) is pleased to update shareholders on the current direction of the Company and other important events.
On February 19, 2014, the Company announced the acquisition of PlasmaGenix Inc., a privately-held California corporation, and now operating as a wholly-owned subsidiary. A Form 8-K reporting this event was filed with the SEC on April 9, 2014.
PlasmaGenix is a life science biologics Company headquartered in Inglewood, California. Their three lead products, PlasmaNeu, PlasmaGen and PlasmaPro have been used for over a decade to treat chronic non-healing wounds, musculoskeletal pathologies, as well as treating patients that suffer from peripheral neuropathy associated with HIV and Diabetes.
PlasmaGenix recently signed a sales agreement with a national network of over 500 healthcare facilities to provide regenerative medicine products and services. To scale up strategically, PlasmaGenix will execute its customer service model in a two-pronged approach. First, PlasmaGenix will implement a pilot program in April 2014 that will include 12 clinics located primarily in the Western U.S. After the completion of the 60-day pilot program, PlasmaGenix will then expand its sales efforts to include numerous facilities throughout the country. This contract is a major milestone for PlasmaGenix as revenues will start increasing during this pilot program.
James Hayes, President and COO of PlasmaGenix, states: "PlasmaGenix is poised for tremendous growth in today’s fragmented market. We feel our products will become the gold standard as we brand PlasmaGenix as a leader in the regenerative medicine sector. Additionally, we are excited about our product pipeline that will include stem sell products derived from both bone marrow and adipose tissue, plasma based wound care dressings, as well as hair restoration and skin rejuvenation product offerings".
The Company announces that it has retained Sadler, Gibb & Associates Certified Public Accountants (PCAOB registered) as the new auditor and recently paid the engagement fee to commence preparation and filing of outstanding financial reports with the SEC. The Company anticipates being fully-reporting within the next 90 to 120 days. This completion will improve internal controls, improve transparency and result in more timely, detailed information about the Company and its ownership. This is a milestone the Company has been working towards and the goal is now achievable. The Form 8-K reporting this event and change in prior auditor was filed on April 8, 2014.
In April 2014, the Company’s the Board of Directors approved the reduction of the total authorized common stock from the current 2,850,000,000 down to 200,000,000 million shares. The Company will be filing an Amendment to the Articles of Incorporation with the Secretary of State of Nevada in the next 30 days to make this affective.
In February 2014, the Company retracted the September 2013 acquisition of X-Fire, Inc., a privately-held Michigan corporation. This rescission was mutually agreed and amicable by both parties. The Company wishes them a great future. Management and the Board of Directors have decided to dedicate all of the Company’s resources to grow and support PlasmaGenix in order to maximize the true valuation of the PlasmaGenix business plan.
Finally, the Company still maintains a 2% interest in a previous joint venture via a settlement agreement that was filed as a Form 8-K on March 22, 2013.
Mike Johnson CEO of Earth Dragon Resources, Inc. states, "It has been a challenging road over the last two years, but we find ourselves on a very exciting path. We are rapidly moving toward being fully-compliant with our SEC reporting requirements and look to further grow of our PlasmaGenix family of innovative products and services both domestic and international. I look forward to assisting PlasmaGenix team in becoming a global leader in the regenerative medicine field.”
Earth Dragon Resources, Inc. will continue to update shareholders on a regular basis as we work to complete the Company’s quarterly and annual reports with the ultimate goal of being reinstated on the OTCQB. All information will be available at sec.gov or the Company’s web site, which is currently being redesigned to reflect the above and we will alert shareholders when it's operable.
I would also like to take this opportunity to thank our Shareholders for their continued support as we build this Company together.
Thank you.
Sincerely,
J. Michael Johnson
President and CEO
Disclaimer:
The press release may include certain statements that are not descriptions of historical facts but are forward looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements may include the description of our plans and objectives for future operations, assumptions underlying such plans and objectives, and other forward-looking terminology such as "may," "expects," "believes," "anticipates," "intends," "projects," or similar terms, variations of such terms or the negative of such terms. There are a number of risks and uncertainties that could cause actual results to differ materially from the forward-looking statements made herein. Such information is based upon various assumptions made by, and expectations of, our management that were reasonable when made but may prove to be incorrect. All of such assumptions are inherently subject to significant economic and competitive uncertainties and contingencies beyond our control and upon assumptions with respect to the future business decisions which are subject to change. Accordingly, there can be no assurance that actual results will meet expectation and actual results may vary (perhaps materially) from certain of the results anticipated herein.
CONTACT:
J. Michael Johnson
President and CEO
Office: 877-865-2283
Email: mike.johnson@earhweb.com
Corporate Address:
Earth Dragon Resources, Inc.
7660-H Fay Ave, Suite 312
La Jolla, CA. 92
http://ih.advfn.com/p.php?pid=nmona&article=61836462
You shouldn't be disappointed. This has winner written all over it.imo exciting times coming.imo
DGI F .01+ next week.imo
DGIF .0045s falling eod might be gone next week.imo
Its got a lot of shares traded already. I would expect with this sort of buying pressure it would move up some. But will see next week. Im thinking .03 easy if someone lets off the ask some.
I got a little bit today. May go in for some more before day is over. Dont want this to fly by me. anything under .01 should be golden.imo
How do they do that? Do they have friends in low places? Cool for free promos.
Darn I just missed .0016 for 500k the other day. wish i had gotten filled but still got my original shares.
EARH .048 following this one. The co recently made an acquisition and 8k it.
If only they could get stock current with SEC this could be a 4 bagger I think pretty easily.
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=9912190
DTEV is really looking alive and good. Got some serious volume for the small OS
Missed those .0125s man i wanted them. just a little extra of this one
One to watch extremely close DGI F Interesting developments. Going to be coming active I hear. They know how to promote this one. It was an all time runner to .70s. if it can just go .10 or .15 that is insane % gainer. imo
Got some .013s myself
Do you have a link?
Whoa what is this DTEV? Maybe I should of loaded the boat?..
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=101451833